GSK4771261 / GSK - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) - P1 | N=86 | Active, not recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Apr 2027 ➔ Jul 2027 | Trial primary completion date: Apr 2027 ➔ Jul 2027

Trial completion date • Trial primary completion date • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) - P1 | N=86 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2026 ➔ Apr 2027 | Trial primary completion date: Sep 2026 ➔ Apr 2027

Enrollment closed • Trial completion date • Trial primary completion date • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Nephrology • Renal Disease

221377: A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive (clinicaltrialsregister.eu) - P1 | N=30 | Not yet recruiting | Sponsor: Glaxosmithkline Research & Development Limited

New P1 trial • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease